Cardica's Nov 2012 Investor Presentation, Slide 36, says that the Microcutter Xchange 30 does not accomodate full tissue range, while Ethicon and Covidien do. This reminds me of the tissue thickness problem with the Xpress 30 that caused Cardica to suspend the clinical trial. Apparently the Xchange 30 clinical trial is stuck at 81 patients. Did Cardica suspend the trial because of tissue thickness problems? Will the FDA require Cardica to label the Xchange 30 with a tissue thickness? Currently it uses the white and blue cartridges. My guess is that surgeons are accustomed to using the white and blue cartridges at customary thicknesses and would have to adapt to using the Xchange 30, making it a tougher sale.
Looks like he may be right? At least that would explain the huge meltdown last week and the market effectrively valuing the microcutter at $0. Frankly, if we have to wait (again) until 3rd qtr next year for a viable product, these guys could be done. Any confirmation that the trial is stuck at 81? I thought maphere said they were still moving it along?